Joel Isaacson & Co. LLC cut its stake in shares of Eli Lilly And Co (NYSE:LLY) by 10.3% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 5,674 shares of the company’s stock after selling 654 shares during the period. Joel Isaacson & Co. LLC’s holdings in Eli Lilly And Co were worth $635,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the company. Enterprise Trust & Investment Co acquired a new position in Eli Lilly And Co in the third quarter valued at approximately $27,000. Prestige Wealth Management Group LLC acquired a new position in Eli Lilly And Co in the second quarter valued at approximately $34,000. Meridian Wealth Management LLC acquired a new position in Eli Lilly And Co in the first quarter valued at approximately $38,000. Manchester Financial Inc. acquired a new position in Eli Lilly And Co in the second quarter valued at approximately $40,000. Finally, Litman Gregory Asset Management LLC acquired a new position in Eli Lilly And Co in the second quarter valued at approximately $47,000. 76.79% of the stock is owned by institutional investors and hedge funds.

NYSE LLY traded down $1.18 on Wednesday, reaching $108.52. The stock had a trading volume of 18,949 shares, compared to its average volume of 2,991,586. The company has a debt-to-equity ratio of 4.98, a quick ratio of 0.87 and a current ratio of 1.13. Eli Lilly And Co has a 12-month low of $104.17 and a 12-month high of $132.13. The business’s 50-day moving average price is $111.36 and its 200 day moving average price is $114.34. The stock has a market cap of $104.61 billion, a P/E ratio of 19.63, a price-to-earnings-growth ratio of 1.88 and a beta of 0.16.

Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings data on Tuesday, July 30th. The company reported $1.50 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.45 by $0.05. Eli Lilly And Co had a return on equity of 70.86% and a net margin of 33.76%. The company had revenue of $5.64 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the previous year, the business earned $1.48 earnings per share. The firm’s revenue for the quarter was up .9% on a year-over-year basis. On average, sell-side analysts predict that Eli Lilly And Co will post 5.72 earnings per share for the current year.

In other Eli Lilly And Co news, SVP Alfonso G. Zulueta sold 4,500 shares of the business’s stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $117.00, for a total value of $526,500.00. Following the completion of the sale, the senior vice president now owns 33,806 shares in the company, valued at $3,955,302. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Stephen F. Fry sold 9,452 shares of the business’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $115.00, for a total value of $1,086,980.00. Following the completion of the sale, the senior vice president now owns 100,211 shares of the company’s stock, valued at approximately $11,524,265. The disclosure for this sale can be found here. In the last quarter, insiders sold 243,452 shares of company stock valued at $28,252,925. 0.11% of the stock is owned by company insiders.

A number of brokerages recently issued reports on LLY. ValuEngine downgraded Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Friday, June 28th. Bank of America set a $120.00 price target on Eli Lilly And Co and gave the company a “neutral” rating in a report on Tuesday, September 10th. Nine equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $122.92.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Recommended Story: Trading Ex-Dividend Strategy

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.